Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
541-560 of 1,743 trials

Multiple Myeloma: Etentamig with Cancer Treatments

We are studying a new drug, Etentamig, combined with standard cancer therapies for adults with relapsed or refractory multiple myeloma. The goal is to assess its safety and impact on disease activity.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Heart Attack Recovery: Ziltivekimab Study

We are investigating how ziltivekimab may improve heart health in people who have had a heart attack compared to a placebo. This study aims to see if it can reduce serious heart-related issues.

Heart Attack>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Late Renal Graft Failure: Immunosuppression Study

We are comparing the effects of continuing versus stopping immunosuppression in patients with late renal graft failure. This study aims to see how these approaches impact health outcomes over two years.

Kidney Transplant>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineNephrology

Rectal Adenocarcinoma: Contact X-Ray Brachytherapy Study

We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.

Rectal Adenocarcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Liver Cancer: Fecal Microbiota Transfer Study

We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHepatologyInternal MedicineOncology

Metastatic Breast Cancer: BGB-43395 Study

We are investigating a new drug for patients with metastatic HR+/HER2- breast cancer and other advanced solid tumors. The study aims to evaluate its safety and early signs of effectiveness, both alone and with other treatments.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Cleft Palate Treatment: Tissue-Engineered Oral Mucosa Substitute

We are testing a new tissue-engineered substitute for patients with cleft palate to see if it is safe and effective for healing and improving quality of life. The study will compare outcomes with standard treatments.

Cleft Lip and Palate>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyOrthopedics and TraumatologyPediatrics

Nerve Damage from Cancer: New Immunotherapy Approach

We are studying a combination of treatments for patients with anti-Hu-associated nerve damage due to cancer. The goal is to see if this early immunotherapy improves symptoms and helps patients live longer without cancer progression.

Paraneoplastic Neurological Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Myeloid Malignancies: PF-08046040/SEA-CD70

We are studying the safety of a new treatment for patients with myeloid malignancies. This research aims to understand how well the treatment is tolerated by patients.

Acute Myeloid LeukaemiaMyelodysplastic Syndrome>2 yearsSafety phase (I)HematologyOncology

Coronary Artery Disease: SYN2 PET Scan Study

We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.

Coronary Artery Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCardiology

Multiple Myeloma: TNB-383B Treatment Study

We are evaluating a new treatment for patients with multiple myeloma to see how safe it is and how well it works. This study will help us understand the maximum dose that can be tolerated.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Bomedemstat for Blood Disorders: Safety and Efficacy Study

We are studying the safety of bomedemstat for individuals with essential thrombocythemia, polycythemia vera, or myelofibrosis who participated in a previous study. The trial also examines how well the treatment manages these conditions over time.

Myeloproliferative Neoplasms>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Triple-Negative Breast Cancer: Keytruda with Chemotherapy

We are studying how different chemotherapy regimens combined with Keytruda affect the immune response in patients with early-stage triple-negative breast cancer. The goal is to find the most effective treatment approach for this specific cancer type.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Coronary Artery Disease: Angiolite Stent and Antiplatelet Therapy Study

We are evaluating whether a new stent and a shorter antiplatelet therapy can reduce complications in patients with coronary artery disease. This study compares these approaches to standard treatment options.

Coronary Artery Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology

Dilated Cardiomyopathy: Candesartan vs Placebo

We are studying whether early treatment with candesartan can help prevent heart function decline in people with a genetic risk for dilated cardiomyopathy who currently have no symptoms. The trial also looks at the safety of this medication.

Dilated Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Plaque Psoriasis: JNJ-77242113 Treatment Study

We are studying a new medication for people with moderate to severe plaque psoriasis. The goal is to see if it works better than a placebo in reducing symptoms.

Plaque Psoriasis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteDermatology

Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

Solid and Hematological Malignancies>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncologyRheumatology

Vitamin D Supplementation in Obese Children and Adolescents

We are comparing monthly versus daily vitamin D supplements to see which is more effective in raising vitamin D levels in obese children and teens. The study also looks at safety and how well participants follow the treatment.

Obesity in Children and Adolescents>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyPediatrics

Advanced Solid Tumors: INCB161734 Treatment

We are testing a new drug for patients with advanced or metastatic solid tumors that have the KRAS G12D mutation. The study aims to understand the safety and dosage of this treatment.

Advanced Cancer>2 yearsSafety phase (I)Oncology